Novo traded 4% lower on the news Friday. Diabetes drug Ozempic and weight-loss drug Wegovy top the list, along with a number of others like Merck's (MRK) diabetes drug Janumet. "The Biden-Harris ...

That is when a new study of the drug is also planned — details were shared in Novo's earnings presentation, released today, and Redefine 4 study results have been promised for H225. Novo stock ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NVO) forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...

In this video, I will go over Novo Nordisk's (NVO-3.62%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Novo Nordisk closed up 4.5% Wednesday. Shares of obesity drug rival Eli Lilly, meanwhile, rose 1.4%. Speaking to CNBC Wednesday, CEO and President Lars Fruergaard Jørgensen said that the company ...

Novo Nordisk Q4 sales rose 30% to around $12 billion. GLP-1 diabetes sales grew 12% to DKK42.2 billion, while obesity drug sales surged 91% to DKK 21.4 billion. Get access to your new suite of ...

Despite the company’s enthusiasm, questions remain about how Novo's latest numbers can move the needle in a competitive market. The company's stock price decline of 4% on Friday seems to ...

Novo Nordisk (NVO) announced Friday that its popular ... the Danish drugmaker said that while patients on regular Wegovy at 2.4 mg achieved 17.5% weight loss over the period, those on placebo ...

The most recent Pod 4 Ultra is currently $150 off all sizes at Eight Sleep. Aimed at hot sleepers and those who want to understand what happens within their sleeping body, the Eight Sleep Pod 4 ...